Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 7/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | RAF1 | P04049 | 8/20 | 0.45 |
| ▸ | BRAF | P15056 | 8/20 | 0.45 |
| ▸ | FADS1 | O60427 | 1/20 | 0.42 |
| ▸ | CD38 | P28907 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19729000 | 0.89 | FADS1 (0.55) | MAPKAPK2KDRRAF1BRAFFADS1 | |
| SCHEMBL19729031 | 0.88 | FADS1 (0.51) | MAPKAPK2KDRRAF1BRAFFADS1 | |
| SCHEMBL17846073 | 0.85 | MAP4K4 (0.53) | KDRRAF1BRAFCD38 | |
| SCHEMBL19729006 | 0.84 | CD38 (0.56) | MAPKAPK2KDRRAF1BRAFCD38 | |
| SCHEMBL19729009 | 0.77 | ALK (0.57) | MAPKAPK2RAF1BRAFCD38 | |
| SCHEMBL19729007 | 0.76 | MAPKAPK2 (0.53) | MAPKAPK2KDRRAF1BRAFFADS1 | |
| SCHEMBL17845965 | 0.73 | EGFR (0.61) | KDRRAF1BRAFFADS1CD38 | |
| SCHEMBL19729011 | 0.73 | MAPKAPK2 (0.47) | MAPKAPK2KDRCD38 | |
| SCHEMBL29793326 | 0.73 | EGFR (0.61) | KDRRAF1BRAFFADS1CD38 | |
| SCHEMBL24009995 | 0.73 | MAPKAPK2 (0.39) | MAPKAPK2RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | MAPKAPK2 156/4885KDR 116/4885RAF1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.